Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 2/2021

Open Access 01-04-2021 | Colorectal Cancer | Original Article

Is a colorectal neoplasm diagnosis a trigger to change dietary and other lifestyle habits for persons with Lynch syndrome? A prospective cohort study

Authors: Jesca G. M. Brouwer, Merel Snellen, Tanya M. Bisseling, Jan Jacob Koornstra, Hans F. A. Vasen, Ellen Kampman, Fränzel J. B. van Duijnhoven

Published in: Familial Cancer | Issue 2/2021

Login to get access

Abstract

A cancer diagnosis is suggested to be associated with changes in dietary and lifestyle habits. Whether this applies to persons with familial cancer, such as Lynch syndrome (LS) is unknown. We investigated whether a colorectal neoplasm (CRN) diagnosis in persons with LS is associated with changes in dietary and lifestyle habits over time. We used data of confirmed LS mutation carriers from the GEOLynch study, a prospective cohort study. Information on dietary intake and lifestyle habits was collected with a validated semi-quantitative food frequency questionnaire and a general questionnaire administered at baseline (2006–2008) and follow-up (2012–2017). Participants’ medical records were used to identify CRN diagnoses. Changes in dietary and lifestyle habits in the CRN and the no-CRN group were compared using multivariable linear regression models for continuous variables and cross-tables with percentage change at follow-up compared with baseline for categorical variables. Of the 324 included participants, 146 developed a CRN (CRN group) between baseline and follow-up, while 178 did not (no-CRN group). Smoking cessation was more often reported in the CRN than in the no-CRN group (41.4% vs. 35.0%). There were no differences in changes of energy intake, alcohol, red meat, processed meat, dairy, fruit, vegetables and dietary fiber consumption, BMI, physical activity and NSAID use. Apart from a potentially higher likelihood of smoking cessation, we found little evidence that a CRN diagnosis is associated with changes in lifestyle habits in persons with LS.
Appendix
Available only for authorised users
Literature
1.
Win AK, Jenkins MA, Dowty JG, Antoniou AC, Lee A, Giles GG, Buchanan DD, Clendenning M, Rosty C et al (2017) Prevalence and penetrance of major genes and polygenes for colorectal cancer. Cancer Epidemiol Biomark Prev 26:404–412
2.
3.
Kempers MJ, Kuiper RP, Ockeloen CW, Chappuis PO, Hutter P, Rahner N, Schackert HK, Steinke V, Holinski-Feder E et al (2011) Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol 12:49–55PubMed
4.
Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Clendenning M, Sotamaa K, Prior T et al (2008) Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26:5783–5788PubMedPubMedCentral
5.
Adan F, Crijns MB, Zandstra WSE, Bekkenk MW, Bleeker FE, Dekker E, van Leerdam ME (2018) Cumulative risk of skin tumours in patients with Lynch syndrome. Br J Dermatol 179:522–523PubMed
6.
Dowty JG, Win AK, Buchanan DD, Lindor NM, Macrae FA, Clendenning M, Antill YC, Thibodeau SN, Casey G et al (2013) Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat 34:490–497PubMed
7.
Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E, Dietmaier W, Schackert HK, Goergens H, von Knebel DM et al (2012) Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol 30:4409–4415PubMed
8.
Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond VM, Bandipalliam P, Stoffel EM, Gruber SB et al (2009) Risk of pancreatic cancer in families with Lynch syndrome. JAMA 302:1790–1795PubMedPubMedCentral
9.
Ryan S, Jenkins MA, Win AK (2014) Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev 23:437–449
10.
South CD, Hampel H, Comeras I, Westman JA, Frankel WL, de la Chapelle A (2008) The frequency of Muir-Torre syndrome among Lynch syndrome families. J Natl Cancer Inst 100:277–281PubMed
11.
ten Broeke SW, Brohet RM, Tops CM, van der Klift HM, Velthuizen ME, Bernstein I, Capella Munar G, Gomez Garcia E, Hoogerbrugge N et al (2015) Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk. J Clin Oncol 33:319–325PubMed
12.
Win AK, Young JP, Lindor NM, Tucker KM, Ahnen DJ, Young GP, Buchanan DD, Clendenning M, Giles GG et al (2012) Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 30:958–964PubMedPubMedCentral
13.
Barrow E, Hill J, Evans DG (2013) Cancer risk in Lynch syndrome. Fam Cancer 12:229–240PubMed
14.
Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, Lindblom A, Lagerstedt K, Thibodeau SN et al (2008) The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 135:419–428PubMedPubMedCentral
15.
Møller P, Seppälä TT, Bernstein I, Holinski-Feder E, Sala P, Gareth Evans D, Lindblom A, Macrae F, Blanco I et al (2018) Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut 67:1306–1316PubMed
16.
Noone AM HN, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA SEER Cancer Statistics Review, 1975–2015, National Cancer Institute. Bethesda, MD. https://​seer.​cancer.​gov/​csr/​1975_​2015/​, based on November 2017 SEER data submission, posted to the SEER web site, April 2018.
17.
Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759–767PubMed
18.
Botma A, Nagengast FM, Braem MG, Hendriks JC, Kleibeuker JH, Vasen HF, Kampman E (2010) Body mass index increases risk of colorectal adenomas in men with Lynch syndrome: the GEOLynch cohort study. J Clin Oncol 28:4346–4353PubMed
19.
Win AK, Dowty JG, English DR, Campbell PT, Young JP, Winship I, Macrae FA, Lipton L, Parry S et al (2011) Body mass index in early adulthood and colorectal cancer risk for carriers and non-carriers of germline mutations in DNA mismatch repair genes. Br J Cancer 105:162–169PubMedPubMedCentral
20.
Diergaarde B, Braam H, Vasen HF, Nagengast FM, van Muijen GN, Kok FJ, Kampman E (2007) Environmental factors and colorectal tumor risk in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol 5:736–742PubMed
21.
Winkels RM, Botma A, Van Duijnhoven FJ, Nagengast FM, Kleibeuker JH, Vasen HF, Kampman E (2012) Smoking increases the risk for colorectal adenomas in patients with Lynch syndrome. Gastroenterology 142:241–247PubMed
22.
Pande M, Lynch PM, Hopper JL, Jenkins MA, Gallinger S, Haile RW, LeMarchand L, Lindor NM, Campbell PT et al (2010) Smoking and colorectal cancer in Lynch syndrome: results from the Colon Cancer Family Registry and the University of Texas M.D. Anderson Cancer Center. Clin Cancer Res 16:1331–1339PubMedPubMedCentral
23.
Watson P, Ashwathnarayan R, Lynch HT, Roy HK (2004) Tobacco use and increased colorectal cancer risk in patients with hereditary nonpolyposis colorectal cancer (Lynch syndrome). Arch Intern Med 164:2429–2431PubMed
24.
Brand RM, Jones DD, Lynch HT, Brand RE, Watson P, Ashwathnayaran R, Roy HK (2006) Risk of colon cancer in hereditary non-polyposis colorectal cancer patients as predicted by fuzzy modeling: Influence of smoking. World J Gastroenterol 12:4485–4491PubMedPubMedCentral
25.
Miguchi M, Hinoi T, Tanakaya K, Yamaguchi T, Furukawa Y, Yoshida T, Tamura K, Sugano K, Ishioka C et al (2018) Alcohol consumption and early-onset risk of colorectal cancer in Japanese patients with Lynch syndrome: a cross-sectional study conducted by the Japanese Society for Cancer of the Colon and Rectum. Surg Today. 48:1–5
26.
Dashti SG, Buchanan DD, Jayasekara H, Ait Ouakrim D, Clendenning M, Rosty C, Winship IM, Macrae FA, Giles GG et al (2017) Alcohol consumption and the risk of colorectal cancer for mismatch repair gene mutation carriers. Cancer Epidemiol Biomark Prev 26:366–375
27.
Botma A, Vasen HF, van Duijnhoven FJ, Kleibeuker JH, Nagengast FM, Kampman E (2013) Dietary patterns and colorectal adenomas in Lynch syndrome: the GEOLynch cohort study. Cancer 119:512–521PubMed
28.
Kamiza AB, Hsieh LL, Tang R, Chien HT, Lai CH, Chiu LL, Lo TP, Hung KY, Wang CY et al (2015) Risk factors associated with colorectal cancer in a subset of patients with mutations in MLH1 and MSH2 in Taiwan Fulfilling the Amsterdam II Criteria for Lynch Syndrome. PLoS ONE 10:e0130018PubMedPubMedCentral
29.
Dashti SG, Win AK, Hardikar SS, Glombicki SE, Mallenahalli S, Thirumurthi S, Peterson SK, You YN, Buchanan DD et al (2018) Physical activity and the risk of colorectal cancer in Lynch syndrome. Int J Cancer 143:2250PubMedPubMedCentral
30.
Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER et al (2011) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378:2081–2087PubMedPubMedCentral
31.
Ait Ouakrim D, Dashti SG, Chau R, Buchanan DD, Clendenning M, Rosty C, Winship IM, Young JP, Giles GG et al (2015) Aspirin, ibuprofen, and the risk of colorectal cancer in lynch syndrome. J Natl Cancer Inst 107:385
32.
Chau R, Dashti SG, Ait Ouakrim D, Buchanan DD, Clendenning M, Rosty C, Winship IM, Young JP, Giles GG et al (2016) Multivitamin, calcium and folic acid supplements and the risk of colorectal cancer in Lynch syndrome. Int J Epidemiol 45:940–953PubMedPubMedCentral
33.
Skeie G, Hjartaker A, Braaten T, Lund E (2009) Dietary change among breast and colorectal cancer survivors and cancer-free women in the Norwegian Women and Cancer cohort study. Cancer Causes Control 20:1955–1966PubMed
34.
Fassier P, Zelek L, Partula V, Srour B, Bachmann P, Touillaud M, Druesne-Pecollo N, Galan P, Cohen P et al (2016) Variations of physical activity and sedentary behavior between before and after cancer diagnosis: results from the prospective population-based NutriNet-Sante cohort. Medicine (Baltimore) 95:4629
35.
Satia JA, Campbell MK, Galanko JA, James A, Carr C, Sandler RS (2004) Longitudinal changes in lifestyle behaviors and health status in colon cancer survivors. Cancer Epidemiol Biomark Prev 13:1022–1031
36.
Karlsen RV, Bidstrup PE, Christensen J, Larsen SB, Tjonneland A, Dalton SO, Johansen C (2012) Men with cancer change their health behaviour: a prospective study from the Danish diet, cancer and health study. Br J Cancer 107:201–206PubMedPubMedCentral
37.
Feunekes GI, Van Staveren WA, De Vries JH, Burema J, Hautvast JG (1993) Relative and biomarker-based validity of a food-frequency questionnaire estimating intake of fats and cholesterol. Am J Clin Nutr 58:489–496PubMed
38.
Verkleij-Hagoort AC, de Vries JH, Stegers MP, Lindemans J, Ursem NT, Steegers-Theunissen RP (2007) Validation of the assessment of folate and vitamin B12 intake in women of reproductive age: the method of triads. Eur J Clin Nutr 61:610–615PubMed
39.
RIVM/Voedingscentrum: NEVO-tabel; Nederlands Voedingsstoffenbestand 2011. Den Haag, 2011
40.
Pols MA, Peeters PH, Bueno-De-Mesquita HB, Ocke MC, Wentink CA, Kemper HC, Collette HJ (1995) Validity and repeatability of a modified Baecke questionnaire on physical activity. Int J Epidemiol 24:381–388PubMed
41.
Baecke JA, Burema J, Frijters JE (1982) A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr 36:936–942PubMed
42.
Willett WC, Howe GR, Kushi LH (1997) Adjustment for total energy intake in epidemiologic studies. Am J Clin Nutr 65:1220S–1228SPubMed
43.
Ramsey S, Blough D, McDermott C, Clarke L, Bennett R, Burke W, Newcomb P (2010) Will knowledge of gene-based colorectal cancer disease risk influence quality of life and screening behavior? Findings from a population-based study. Public Health Genomics 13:1–12PubMed
44.
Brodersen NH, Sutton S, Goff S, Hodgson SV, Thomas HJ (2004) Anticipated reactions to genetic testing for hereditary non-polyposis colorectal cancer susceptibility. Clin Genet 66:437–444PubMed
45.
Kim JS, Coyte PC, Cotterchio M, Keogh LA, Flander LB, Gaff C, Laporte A (2016) The impact of receiving predictive genetic information about lynch syndrome on individual colonoscopy and smoking behaviors. Cancer Epidemiol Biomark Prev 25:1524–1533
46.
Visser A, Vrieling A, Murugesu L, Hoogerbrugge N, Kampman E, Hoedjes M (2017) Determinants of adherence to recommendations for cancer prevention among Lynch Syndrome mutation carriers: a qualitative exploration. PLoS ONE 12:e0178205PubMedPubMedCentral
Metadata
Title
Is a colorectal neoplasm diagnosis a trigger to change dietary and other lifestyle habits for persons with Lynch syndrome? A prospective cohort study
Authors
Jesca G. M. Brouwer
Merel Snellen
Tanya M. Bisseling
Jan Jacob Koornstra
Hans F. A. Vasen
Ellen Kampman
Fränzel J. B. van Duijnhoven
Publication date
01-04-2021
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 2/2021
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-020-00201-5

Other articles of this Issue 2/2021

Familial Cancer 2/2021 Go to the issue

Original Article

Characterizing germline APC and MUTYH variants in Ashkenazi Jews compared to other individuals

Letter to the Editor

Letter to the Editor-Recent advances in Lynch syndrome

Correction

Correction to: Letter to the Editor—Recent advances in Lynch syndrome: response to Møller et al.

Original Article

Clinical phenotypes combined with saturation genome editing identifying the pathogenicity of BRCA1 variants of uncertain significance in breast cancer

Letter to the Editor

Letter to the Editor-Recent advances in Lynch syndrome: response to Møller et al.

Original Article

Worldwide variation in lynch syndrome screening: case for universal screening in low colorectal cancer prevalence areas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits